← back to search

Ke Xu

Hebei Medical University · CN
Area of research
Cancer Research · Oncology
Research interest
Research interests include MicroRNA in disease regulation, Cancer-related molecular mechanisms research, Cancer Cells and Metastasis, and Cancer, Hypoxia, and Metabolism.
h-index
45
citations
5,906
works
202
NIH funding
primary concept
email

Recent publications

Clinical features of abdominal migraine: a systematic review and summary of data from 662 patients
Frontiers in Neurology 2026cited by 1position: middledoi
NRT1.1B acts as an abscisic acid receptor in integrating compound environmental cues for plants
Cell 2025cited by 51position: middledoi
Biomimetic Extracellular Vesicles Containing Biominerals for Targeted Osteoporosis Therapy
ACS Applied Materials & Interfaces 2025cited by 6position: middledoi
Dose and local efficacy analysis of iodine-125 seed implantation therapy for lung tumors
Frontiers in Oncology 2025cited by 1position: middledoi
Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study
Renal Failure 2025cited by 0position: middledoi
Advanced glycation end products mediate biomineralization disorder in diabetic bone disease
Cell Reports Medicine 2024cited by 56position: middledoi
CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1
Journal of Experimental & Clinical Cancer Research 2024cited by 28position: middledoi
Single-cell RNA sequencing to explore cancer-associated fibroblasts heterogeneity: "Single" vision for "heterogeneous" environment.
2024cited by 26position: contributordoi
Dose and local efficacy analysis of iodine-125 seed implantation therapy for lung tumors
Research Square 2024cited by 0position: middledoi
CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer
Frontiers in Oncology 2023cited by 3position: middledoi
Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases.
2022cited by 44position: contributordoi
Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis
Frontiers in Cardiovascular Medicine 2022cited by 42position: middledoi
Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles.
2021cited by 93position: contributordoi
Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer.
2021cited by 44position: contributordoi
Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway.
2021cited by 40position: contributordoi
Eudragit S100 prepared pH-responsive liposomes-loaded betulinic acid against colorectal cancer <i>in vitro</i> and <i>in vivo</i>
Journal of Liposome Research 2021cited by 34position: middledoi
The Anti-Tumor Effect and Mechanism of Triterpenoids in <i>Rhus chinensis</i> Mill. on Reversing Effector CD8+ T-cells Dysfunction by Targeting Glycolysis Pathways in Colorectal Cancer
Integrative Cancer Therapies 2021cited by 17position: middledoi
Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signaling pathway
2021cited by 0position: contributordoi
β-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.
2020cited by 56position: contributordoi
Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer.
2020cited by 51position: contributordoi
Bufalin reverses multidrug resistance by regulating stemness through the CD133/nuclear factor-κB/MDR1 pathway in colorectal cancer.
2020cited by 36position: contributordoi
The effects and mechanisms of isoliquiritigenin loaded nanoliposomes regulated AMPK/mTOR mediated glycolysis in colorectal cancer
Artificial Cells Nanomedicine and Biotechnology 2020cited by 32position: middledoi
Effects and mechanisms of fatty acid metabolism‑mediated glycolysis regulated by betulinic acid‑loaded nanoliposomes in colorectal cancer
Oncology Reports 2020cited by 19position: lastdoi
cRGD-Conjugated Fe<sub>3</sub>O<sub>4</sub>@PDA-DOX Multifunctional Nanocomposites for MRI and Antitumor Chemo-Photothermal Therapy.
2019cited by 32position: contributordoi
Triterpenoids Extracted from<i>Rhus chinensis Mill</i>Act Against Colorectal Cancer by Inhibiting Enzymes in Glycolysis and Glutaminolysis: Network Analysis and Experimental Validation
Nutrition and Cancer 2019cited by 28position: lastdoi
SnoN residue (1-366) attenuates hypertrophic scars through resistance to transforming growth factor-β1-induced degradation.
2019cited by 5position: contributordoi
New strategies for targeting glucose metabolism–mediated acidosis for colorectal cancer therapy
Journal of Cellular Physiology 2018cited by 66position: middledoi
Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction
Journal of Hematology & Oncology 2018cited by 48position: middledoi
MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling
Scientific Reports 2017cited by 159position: firstdoi
miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma
Oncotarget 2017cited by 55position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

· 6 papers (2019–2024)Yang Yu · Guangzhou University of Chinese Medicine5 papers (2019–2021)Xin Liang · Xi'an University of Architecture and Technology3 papers (2017–2018)Gang Wang · Jiangsu University3 papers (2018–2021)Junjie Wang · Qingdao Agricultural University3 papers (2018–2021)Hongtao Zhang · Zhejiang A & F University3 papers (2023–2025)Xiaojing Chang · Hebei Medical University3 papers (2023–2025)Juan Wang · Hebei Medical University2 papers (2024–2025)Gang Wang · Jiangsu University2 papers (2019–2020)Guo Chen · Guiyang College of Traditional Chinese Medicine2 papers (2017–2017)Zeyang Wang · Capital Medical University2 papers (2024–2025)Qinglin Han · Kunming University of Science and Technology2 papers (2024–2025)Jiacan Su · The First Affiliated Hospital, Sun Yat-sen University2 papers (2024–2025)Xiaoli Liu · Sun Yat-sen University2 papers (2024–2025)Guohui Cao · Hebei General Hospital2 papers (2024–2025)Yingying Jiang · Shandong University of Technology2 papers (2024–2025)Mengru Zhu · Guangzhou University of Chinese Medicine2 papers (2024–2025)Hao Shen · Shandong University of Technology1 papers (2024–2024)Yanyan Qiu · Shanghai Medical College of Fudan University1 papers (2017–2017)Binghua Tan · Sun Yat-sen University1 papers (2024–2024)